EP0282618A1
Expired / Lapsed
EP
⏱️ 0.0 years remaining
1-Deoxynojirimycin as an anti-HIV therapeutic
Assignee: Stichting Vrienden Van de Stichting Dr Karl Landsteiner
•
Filing: 1987-03-18
•
Granted: —
•
Expires: 2007-03-18
Abstract
Abstract There is described the use of 1-deoxynojirimycin of the formula and pharmaceutically acceptable acid addition salts thereof, optionally, in combination with an agent that specifically interferes with the replication and/or expression of the viral genome of HIV or parts thereof for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Inventors
- 👤 Frank Dr. Miedema
- 👤 Hidde Lolke Dr. Ploegh
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-08 16:28
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K31/445
Claims Analysis
Total Claims: 25
Claim 1
Independent Claim
65 words
The use of 1-deoxynojirimycin of the formula or of a pharmaceutically acceptable acid addition salt thereof, optionally, in combination with an agent that specifically interferes with the replication and/or expression of the viral genome of HIV or parts thereof and/or an other therapeutically valuable substance in the manufacture of pharmaceutical compositions for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 2
Dependent Claim
65 words
The use of 1-deoxynojirimycin of the formula or of a pharmaceutically acceptable acid addition salt thereof, optionally, in combination with an agent that specifically interferes with the replication and/or expression of the viral genome of HIV or parts thereof and/or an other therapeutically valuable substance in the manufacture of pharmaceutical compositions for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 3
Dependent Claim
59 words
The use of 1-deoxynojirimycin in form of the free base, optionally, in combination with an agent that specifically interferes with the replication and/or expression of the viral genome of HIV or parts thereof and/or an other therapeutically valuble usbstance in the manufacture of pharmaceutical compositions for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 4
Dependent Claim
59 words
The use of 1-deoxynojirimycin in form of the free base, optionally, in combination with an agent that specifically interferes with the replication and/or expression of the viral genome of HIV or parts thereof and/or an other therapeutically valuble usbstance in the manufacture of pharmaceutical compositions for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 5
Dependent Claim
29 words
The use of 1-deoxynojirimycin in form of free base in the manufacture of pharmaceutical compositions for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 6
Dependent Claim
29 words
The use of 1-deoxynojirimycin in form of free base in the manufacture of pharmaceutical compositions for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 7
Dependent Claim
41 words
A pharmaceutical composition comprising 1-deoxynojirimycin of the formula or a pharmaceutically acceptable acid addition salt thereof, an agent that specifically interferes with the replication and/or expression of the viral genome of HIV or parts thereof and a therapeutically inert carrier material.
Claim 8
Dependent Claim
41 words
A pharmaceutical composition comprising 1-deoxynojirimycin of the formula or a pharmaceutically acceptable acid addition salt thereof, an agent that specifically interferes with the replication and/or expression of the viral genome of HIV or parts thereof and a therapeutically inert carrier material.
Claim 9
Dependent Claim
15 words
A pharmaceutical composition according to claim 4, comprising 1-deoxynojirimycin in form of the free base.
Claim 10
Dependent Claim
16 words
A pharmaceutical composition according to claim 4 or 5, wherein said agent is 3ʹ-azido-3ʹ-deoxythymidine or 2ʹ,3ʹ--dideoxycytidine.
Claim 11
Independent Claim
47 words
A method of treating and/or preventing AIDS and AIDS related diseases caused by HIV in a human being which comprises administering to said patient an effective amount of 1-deoxynojirimycin of the formula or a pharmaceutically acceptable acid addition salt thereof together with a therapeutically inert carrier material.
Claim 12
Independent Claim
47 words
A method of treating and/or preventing AIDS and AIDS related diseases caused by HIV in a human being which comprises administering to said patient an effective amount of 1-deoxynojirimycin of the formula or a pharmaceutically acceptable acid addition salt thereof together with a therapeutically inert carrier material.
Claim 13
Dependent Claim
16 words
A method in accordance with claim 7, wherein 1-deoxynojirimycin is usedin form of the free base.
Claim 14
Dependent Claim
39 words
A method in accordance with claim 7 or 8, wherein an effective amount of an agent that specifically interferes with the replication and/or expression of the viral genome of HIV or parts thereof is administered previously, simultaneously or subsequently.
Claim 15
Dependent Claim
14 words
A method in accordance with claim 9, wherein said agent is 3ʹ-azido-3ʹ-deoxythymidine or 2ʹ,3ʹ-dideoxycytidine.
Claim 16
Dependent Claim
59 words
The use of 1-deoxynojirimycin of the formula or of a pharmaceutically acceptable acid addition salt thereof, optionally, in combination with an agent that specifically interferes with the replication and/or expression of the viral genome of HIV or parts thereof or an other therapeutically valuable substance for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 17
Dependent Claim
59 words
The use of 1-deoxynojirimycin of the formula or of a pharmaceutically acceptable acid addition salt thereof, optionally, in combination with an agent that specifically interferes with the replication and/or expression of the viral genome of HIV or parts thereof or an other therapeutically valuable substance for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 18
Dependent Claim
53 words
The use of 1-deoxynojirimycin in form of the free base, optionally, in combination with an agent that specifically interferes with the replication and/or expression of the viral genome of HIV or parts thereof or an other therapeutically valuable substance for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 19
Dependent Claim
53 words
The use of 1-deoxynojirimycin in form of the free base, optionally, in combination with an agent that specifically interferes with the replication and/or expression of the viral genome of HIV or parts thereof or an other therapeutically valuable substance for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 20
Dependent Claim
24 words
The use of 1-deoxynojirimycin in form of the free base for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 21
Dependent Claim
24 words
The use of 1-deoxynojirimycin in form of the free base for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 22
Dependent Claim
31 words
The use of 1-deoxynojirimycin in form of the free base, optionally, in combination with 3ʹ-azido-3ʹ-deoxythymidine or 2ʹ,3ʹ-dideoxycytidine for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 23
Dependent Claim
31 words
The use of 1-deoxynojirimycin in form of the free base, optionally, in combination with 3ʹ-azido-3ʹ-deoxythymidine or 2ʹ,3ʹ-dideoxycytidine for the treatment and/or prevention of AIDS and AIDS related diseases caused by HIV.
Claim 24
Dependent Claim
5 words
The invention as hereinbefore described.
Claim 25
Dependent Claim
5 words
The invention as hereinbefore described.
References Cited (Backward Citations)
EP0196185A2
Cited
WO1987003903A1
Cited
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.